- Home
- CURI vs VTYX Comparison
CURI vs VTYX Comparison
Compare CURI & VTYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CURI
- VTYX
- Stock Information
- Founded
- CURI N/A
- VTYX 2018
- Country
- CURI United States
- VTYX United States
- Employees
- CURI N/A
- VTYX N/A
- Industry
- CURI Movies/Entertainment
- VTYX Medicinal Chemicals and Botanical Products
- Sector
- CURI Consumer Discretionary
- VTYX Health Care
- Exchange
- CURI Nasdaq
- VTYX Nasdaq
- Market Cap
- CURI 144.8M
- VTYX 154.9M
- IPO Year
- CURI N/A
- VTYX 2021
- Fundamental
- Price
- CURI $4.99
- VTYX $1.24
- Analyst Decision
- CURI Strong Buy
- VTYX Buy
- Analyst Count
- CURI 2
- VTYX 4
- Target Price
- CURI $5.40
- VTYX $11.33
- AVG Volume (30 Days)
- CURI 911.2K
- VTYX 982.1K
- Earning Date
- CURI 05-06-2025
- VTYX 05-08-2025
- Dividend Yield
- CURI 1.80%
- VTYX N/A
- EPS Growth
- CURI N/A
- VTYX N/A
- EPS
- CURI N/A
- VTYX N/A
- Revenue
- CURI $54,223,000.00
- VTYX N/A
- Revenue This Year
- CURI $14.45
- VTYX N/A
- Revenue Next Year
- CURI $10.55
- VTYX N/A
- P/E Ratio
- CURI N/A
- VTYX N/A
- Revenue Growth
- CURI N/A
- VTYX N/A
- 52 Week Low
- CURI $0.98
- VTYX $0.78
- 52 Week High
- CURI $5.30
- VTYX $5.66
- Technical
- Relative Strength Index (RSI)
- CURI 77.52
- VTYX 50.66
- Support Level
- CURI $3.21
- VTYX $1.15
- Resistance Level
- CURI $5.30
- VTYX $1.48
- Average True Range (ATR)
- CURI 0.37
- VTYX 0.11
- MACD
- CURI 0.15
- VTYX 0.01
- Stochastic Oscillator
- CURI 86.28
- VTYX 44.19
About CURI CuriosityStream Inc.
CuriosityStream Inc is a media and entertainment company. It offers premium video programming across the principal categories of factual entertainment, including science, history, society, nature, lifestyle, and technology. Its mission is to provide premium real entertainment that informs, enchants, and inspires. Its product and services are Direct to Consumer Business, Partner Direct Business, Bundled Distribution, Content Licensing, Enterprise Subscriptions, and Others. The majority of the revenue comes from the Direct to direct-to-consumer business.
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.